| 生物活性 |
Kukoamine A is an orally active, blood-brain barrier-penetrating spermine alkaloid found in the root bark of Lycium chinense (L. chinense) Miller that inhibits purified Trypanosoma brucei brucei trypanothione reductase and soybean lipoxygenase and activates the μ-opioid receptor, thereby inhibiting cancer cell proliferation, migration, and invasion, inducing G0/G1 cell cycle arrest and apoptosis, exerting neuroprotective effects and inducing autophagy, inhibiting LPS (MS-X54539)-induced production of NO, ROS, PGE2, TNF-α, IL-1β, and IL-6 as well as COX-2 activity, and reversing palmitic acid-induced insulin resistance, lipid accumulation, and oxidative stress via downregulation of Srebp-1c, making it useful for research on cancer, infection, inflammation, metabolic diseases, and neurological diseases such as glioblastoma and Parkinson's disease. |
| IC50 & Target |
Trypanothione reductase:1.8 microM(Ki), LOX:9.5 microM |
体外研究 (In Vitro) |
Kukoamine A 作为混合型抑制剂可强效抑制纯化的 Crithidia fasciculata 锥虫硫醇还原酶,其 Ki 为 1.8 μM、对酶-底物复合物的 Kii 为 13 μM,而对人谷胱甘肽还原酶无显著抑制作用。 Kukoamine A (0.1 mM; 20-60 min) 表现出较强的 DPPH 自由基清除活性,在无细胞体系中孵育 20 min 和 60 min 后,0.1 mM 浓度下的还原活性均为 96%。 Kukoamine A 可强效抑制无细胞体系中的大豆脂氧合酶,其 IC50 为 9.5 μM。 Kukoamine A (0.1 mM) 可抑制 72% 的 AAPH 诱导亚油酸脂质过氧化反应。 Kukoamine A 可通过下调 Srebp-1c 逆转 AML-12 细胞中 palmitic acid 诱导的胰岛素抵抗、脂质蓄积和氧化应激,而 Srebp-1c 的过表达会消除这些保护作用。 Kukoamine A (10-80 μg/mL;作用 1-5 天) 以时间和剂量依赖的方式选择性抑制人胶质母细胞瘤 U251 和 WJ1 细胞的活力,在作用第 5 天时其 IC50 值分别为 73.4 μg/mL 和 22.1 μg/mL,而对人正常肝细胞 LO2 和大鼠胶质瘤 C6 细胞的影响极小。 Kukoamine A (5-20 μg/mL; 12 days) 以剂量依赖的方式抑制人胶质母细胞瘤 U251 和 WJ1 细胞的克隆形成能力。 Kukoamine A (10-80 μg/mL;48 h) 以剂量依赖方式诱导人胶质母细胞瘤 U251 和 WJ1 细胞发生凋亡,下调 5-LOX 和抗凋亡蛋白 Bcl-2 的表达,并上调促凋亡蛋白 Bax 和活化型 caspase-3 的表达。 Kukoamine A (5-20 μg/ml;48 h) 以剂量依赖的方式诱导人胶质母细胞瘤 U251 和 WJ1 细胞发生 G0/G1 期细胞周期阻滞。 Kukoamine A (10-80 μg/mL;24 h) 可呈剂量依赖性抑制人胶质母细胞瘤 U251 细胞和 WJ1 细胞的迁移和侵袭。 Kukoamine A (10-40 μM;预孵育 4 h,随后与 MPP+ 共孵育 24 h) 可呈剂量依赖性地保护 SH-SY5Y 细胞免受 MPP+ 诱导的损伤,抑制凋亡并维持线粒体膜电位。 Kukoamine A (10-40 μM;预孵育 4 h,随后与 MPP+共孵育 24 h) 在 SH-SY5Y 细胞中呈剂量依赖性地降低 Bax/Bcl-2 比率、p-JNK 和 p-p38 水平,并增加 p-AKT、p-ERK 水平。 Kukoamine A (10-40 μM;4 h) 可在 SH-SY5Y 细胞中呈剂量依赖性诱导自噬,在最高浓度下可诱导形成可见的自噬体,,增加 LC3-II/LC3-I 的比值、Beclin-1 的水平,并降低 p62 的水平。 Kukoamine A 可高亲和力结合 HEK293T 细胞膜上表达的人 μ 型阿片受体,其 Ki 值为 1.3 ± 0.18 μM,EC50 值为 5.6 ± 0.65 μM。 Kukoamine A (5-40 μM;24 h) 不会降低 RAW 264.7 巨噬细胞的存活率。 Kukoamine A (5-40 μM;24 h) 以浓度依赖的方式显著抑制 LPS (MS-X54539) 诱导的 RAW 264.7 巨噬细胞中 NO、ROS、PGE2、TNF-α、IL-1β 和 IL-6 的 的生成。 Kukoamine A (5-40 μM) 可显著抑制 LPS 诱导的 RAW 264.7 巨噬细胞中 COX-2 活性。
Apoptosis Analysis
| Cell Line: |
human glioblastoma U251 cells, human glioblastoma WJ1 cells |
| Concentration: |
40, 60, 80 μg/ml (U251 cells); 10, 20, 30 μg/ml (WJ1 cells) |
| Incubation Time: |
48 h |
| Result: |
Induced a significant, dose-dependent increase in both early and late apoptotic cells, as well as total apoptotic cells, in both U251 and WJ1 cells compared to untreated controls. |
Cell Cycle Analysis
| Cell Line: |
human glioblastoma U251 cells, human glioblastoma WJ1 cells |
| Concentration: |
5, 10, 20 μg/ml |
| Incubation Time: |
48 h |
| Result: |
Caused a significant, dose-dependent increase in the cell population in the G0/G1 phase in both U251 and WJ1 cells compared to untreated controls. Caused a corresponding significant, dose-dependent decrease in the cell population in the S phase in both U251 and WJ1 cells compared to untreated controls. |
Western Blot Analysis
| Cell Line: |
human glioblastoma U251 cells, human glioblastoma WJ1 cells |
| Concentration: |
40, 60, 80 μg/ml (U251 cells); 10, 20, 30 μg/ml (WJ1 cells) |
| Incubation Time: |
48 h |
| Result: |
Caused a dose-dependent decrease in 5-LOX and Bcl-2 protein expression in U251 and WJ1 cells. Caused a dose-dependent increase in Bax and active caspase-3 protein expression in U251 and WJ1 cells. Caused a dose-dependent decrease in C/EBPβ, N-cadherin, vimentin, twist, and snail+slug protein expression in U251 and WJ1 cells. Caused a dose-dependent increase in E-cadherin protein expression in U251 and WJ1 cells. |
Western Blot Analysis
| Cell Line: |
MPP⁺-treated SH-SY5Y human neuroblastoma cells |
| Concentration: |
10 μM, 20 μM, 40 μM |
| Incubation Time: |
4 h pre-incubation, followed by 24 h co-incubation with MPP⁺ |
| Result: |
Decreased the Bax/Bcl-2 ratio to 3.77 ± 0.36, 2.22 ± 0.17, and 0.68 ± 0.31 at 10, 20, and 40 μM, respectively. Increased p-AKT levels to 2.05 ± 0.07. Increased p-ERK levels to 3.31 ± 0.14. Decreased p-JNK levels to 0.57 ± 0.02. Decreased p-p38 levels to 0.21 ± 0.06 compared to MPP⁺-treated cells.
|
ELISA Assay
| Cell Line: |
LPS-stimulated RAW 264.7 macrophage cells |
| Concentration: |
5, 10, 20, 40 μM |
| Incubation Time: |
12 h (pretreatment); 12 h (LPS stimulation) |
| Result: |
Significantly attenuated LPS-induced increases in TNF-α, IL-1β, and IL-6 levels in a concentration-dependent manner, with all tested concentrations showing statistically significant inhibition relative to LPS-only treated cells. Significantly reduced LPS-induced PGE2 levels, with all tested concentrations showing statistically significant inhibition relative to LPS-only treated cells. Markedly inhibited LPS-induced COX-2 activity.
|
|
体内研究 (In Vivo) |
Kukoamine A (0.01 mmol/kg;腹腔注射;单剂量) 可将 Carrageenan (MS-L60716) 诱导的大鼠足爪水肿抑制 43%。 Kukoamine A (5-20 mg/kg;腹腔注射;每日给药;持续 4 周) 可通过抑制 Srebp-1c 及其下游靶基因的表达,以剂量依赖的方式缓解小鼠中高脂饮食诱导的胰岛素抵抗、脂肪肝、炎症及氧化应激。 Kukoamine A (10-40 mg/kg;腹腔注射;每周 5 次;持续 4 周) 可呈剂量依赖性抑制胶质母细胞瘤的体内生长,在 40 mg/kg 剂量下肿瘤抑制率最高可达 55.3%,同时不会降低小鼠体重;其作用机制为通过下调 5-LOX 和 C/EBPβ 的表达,诱导细胞凋亡并减弱上皮-间质转化。 Kukoamine A (5-20 mg/kg;灌胃;每日给药,连续 12 天) 通过改善运动功能、减少神经元凋亡、降低 α-突触核蛋白水平、保留多巴胺能神经元并增强自噬的方式,在 MPTP (MS-O89430) 诱导的帕金森病小鼠模型中发挥剂量依赖性神经保护作用,且不影响 MAO-B 活性。 Kukoamine A (5-20 mg/kg;灌胃;每日给药,连续 12 天) 可通过调控自噬相关蛋白增强健康小鼠黑质 (SN) 和纹状体 (Str) 中的自噬水平,且不会诱导细胞凋亡或改变 MAO-B 活性。 Kukoamine A (25-50 mg/kg;口服;每日给药,连续 5 天) 对 Carrageenan (MS-L60716) 诱导急性炎症的大鼠具有浓度依赖性抗炎与抗氧化作用,可减轻足爪肿胀、降低促炎细胞因子水平及氧化应激标志物水平,同时提升肝脏抗氧化酶活性。
| Animal Model: |
Carrageenan-induced edema Fischer-344 rats (male and female, 150-200 g, non-pregnant females; 6-15 animals per group) |
| Dosage: |
0.01 mmol/kg |
| Administration: |
I.p.; single dose |
| Result: |
Inhibited carrageenan-induced rat paw edema by 43%. |
| Animal Model: |
C57 (6-8 weeks old; high fat diet-induced model) |
| Dosage: |
5 mg/kg; 10 mg/kg; 20 mg/kg |
| Administration: |
I.p.; daily; 4 weeks |
| Result: |
Dose-dependently inhibited HFD-induced increases in fasting blood glucose and insulin levels, and dose-dependently reduced glucose levels in response to glucose and insulin loads during IPGTT and IPITT. Dose-dependently decreased HFD-induced liver histological injury, hepatic triglyceride levels, and serum AST and ALT activities. Dose-dependently inhibited HFD-induced increases in serum TNFα, IL-1β, IL-6, and C reactive protein levels. Dose-dependently reversed HFD-induced reductions in hepatic MnSOD and CuZnSOD activities, and dose-dependently inhibited HFD-induced increases in hepatic MDA and H2O2 levels. Dose-dependently inhibited HFD-induced upregulation of hepatic Srebp-1c protein and mRNA expression, as well as hepatic mRNA expression of the Srebp-1c target genes FAS and ACC1. |
| Animal Model: |
BALB/C-nu/nu nude mice (5-week-old, male, intraperitoneal inoculation of human GBM WJ1 cells) |
| Dosage: |
10 mg/kg; 20 mg/kg; 40 mg/kg |
| Administration: |
I.p.; 5 times weekly; 4 weeks |
| Result: |
Reduced mean tumor weight. Achieved tumor inhibitory rates of 35.2%, 48.8%, and 55.3% at 10, 20, and 40 mg/kg doses, respectively. Showed no difference in body weight increase compared to control mice. Significantly decreased 5-LOX, Bcl-2, C/EBPβ, N-cadherin, vimentin, twist, and snail+slug protein expression in tumor tissues in a dose-dependent manner. Significantly increased Bax, active caspase-3, and E-cadherin protein expression in tumor tissues in a dose-dependent manner. |
| Animal Model: |
C57BL/6 (male, 7~8 weeks old, 20~22 g, MPTP-induced modeling) |
| Dosage: |
5 mg/kg; 20 mg/kg |
| Administration: |
I.g.; daily; 12 days |
| Result: |
Increased the time mice stayed on the rota-rod, reduced the time to climb down the pole, and increased traction test scores at all tested time points compared to MPTP-only mice. Increased the level of Nissl substance in the substantia nigra (SN), reversed the MPTP-induced increase in Bax and cytochrome c expression, reversed the decrease in Bcl-2 expression, and reduced caspase-3 activity in both SN and striatum (Str) in a dose-dependent manner. Decreased MPTP-induced α-synuclein elevation in SN and Str, attenuated MPTP-induced loss of tyrosine hydroxylase (TH)-positive cells in SN and Str, and attenuated MPTP-induced reduction in TH protein levels in SN and Str. Upregulated the LC3-II/LC3-I ratio and Beclin-1 expression, and downregulated p62 expression in both SN and Str.\nDid not alter MAO-B activity in the brain. |
| Animal Model: |
Carrageenan-induced Wistar rats (male, 180-220 g) |
| Dosage: |
25 mg/kg; 50 mg/kg |
| Administration: |
P.o.; daily; 5 days |
| Result: |
Significantly reduced carrageenan-induced paw edema volume in a concentration-dependent manner over the 4-hour observation period. Significantly reduced serum levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6. Significantly increased liver activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px). Significantly reduced liver malondialdehyde (MDA) levels.\nAll results were statistically significant. |
|
| 性状 |
固体 |
| 颜色 |
White to off-white |